Theme: Translational Research

Invited Speakers on the Theme of Translational Research

Symposium – Neuroendocrine Therapeutics: What’s the Latest?

Dr. Jean BOUTIN, Institut de Recherches Internationales Servier, France

Jean A. Boutin graduated (Thèse d’Etat ès Sciences Biologiques) from the Université de Nancy (France) on drug metabolism (UGT). He did two postdoctoral training periods at Johns Hopkins University School of Medicine (Baltimore) and at the Karolinska Institutet (Stockholm, Sweden). He was hired as protein chemist in Les Laboratoires SERVIER (LLS) in 1986. During the 30ish last years, Dr. Boutin moved from oncology to peptide research and then molecular & cellular pharmacology. Recently, LLS created a drug discovery platform that Dr. Boutin led until October, 1st, 2016. Since then, he is Directeur de la Prospective particularly in the technological areas associated with molecular pharmacology. These areas include, but are not limited to drug molecular modeling, ligand/protein biophysical interaction measurements, protein chemistry, stem cells, structural biology, chemogenetics, HTS, biologics…The main interests of Dr. Boutin are N-myristoyltransferase, melatonin, quinone reductase 2, MCH and autotaxin. He published about 250 scientific papers and book chapters.

Dr. Waljit DHILLO, Imperial College London, UK

 Clinical Studies with Kisspeptin

Waljit Dhillo is Professor of Endocrinology & Metabolism and Consultant Endocrinologist at Imperial College London. He completed his medical training at St Bartholomew’s Hospital Medical School, University of London. During this time he completed an Intercalated BSc (First Class Honours) in Biochemistry funded by the Medical Research Council. Subsequently during his clinical training he completed a PhD as a Wellcome Trust Clinical Training Fellow at Imperial College. He was subsequently awarded 3 National Institute for Health Research (NIHR) personal Fellowships – Clinician Scientist Fellowship 2004-2009, Career Development Fellowship 2009-2015 and most recently a Research Professorship 2015-2020. He was appointed to a personal Chair at Imperial College in 2011. He has published 156 articles and a h-index of 36 (Web of Science).

 Dr. Paul Emmerson, Eli Lilly and Company, Indianapolis, IN, USA

The role of GDF15 and its receptor GFRAL in the regulation of food intake and body weight

Paul Emmerson is currently a Research Advisor in the Diabetes, Incretin Discovery Group at Eli Lilly and Company. He received his doctorate in pharmacology from the University of Michigan and completed a National Institute on Drug Abuse supported post-doctoral fellowship in Dr. Richard Miller’s laboratory at The University of Chicago where he studied the function of orexigenic neuropeptides in the hypothalamus. He joined Eli Lilly in 2000 where his group has been focused on the discovery of novel therapeutics for obesity and type 2 diabetes through targeting peptide and protein receptors in the hypothalamus and brain stem involved in the regulation of food intake and body weight.

Dr. Kerstin STEMMER, Helmholtz Zentrum Muenchen, Germany

Readjusting Gut-Brain Signalling with Unimolecular Polyagonists: Translational Potential

Dr. Stemmer’s academic research is directed towards elucidating novel strategies for the early detection and personalized therapy of metabolic dysfunction and related comorbidities. She currently explores the diagnostic value and functionality of extracellular vesicles for metabolic diseases. Moreover, she is part of a joint team of scientists from academia and NovoNordisk that aims to develop novel peptide based anti-obesity drugs.

She earned her Master and PhD in Human and Environmental Toxicology at the University of Konstanz, Germany. In paralell she pursued the postgraduate educational program of the German Society of Pharmacology and Toxicology, which allowed her to register as toxicologist. She continued her postgraduate training in the laboratory of Professors Stephen Woods and Randy Seeley at the Metabolic Diseases Institute in Cincinnati, OH. In April 2012 she returned to Europe to work at her current tenured position as head of the Division of Pharmacology and Toxicology at the Institute for Diabetes and Obesity, Helmholtz Centre Munich, Germany. In July 2018, she received an additional appointment as senior lecturer at the University of Konstanz.

Her research was honored with the outstanding PhD thesis award provided by the pharmaceutical company Nycomed, and the Erwin Schrödinger Award by the Helmholtz Society.

Dr. Michael TROWER, KaNDy Therapeutics Ltd, UK

Reducing the Heat with Neurokinin Antagonism; A New Non-Hormonal Approach for Treating Hot Flashes

Mike Trower is Chief Scientific Officer of KaNDy Therapeutics a company dedicated to developing breakthrough treatments for debilitating Women’s Health conditions. He has more than 25 years’ drug discovery and development experience in the pharmaceutical and biotechnology industries. Prior to KaNDy, Mike worked at GlaxoSmithKline, where he was Head of the External Drug Discovery Group in the Neurosciences Division.  He has broad expert knowledge of neurokinin receptor system biology and in particular how it relates to KNDy neuronal activity.  Mike has a BSc (Hons) and a PhD in biological sciences and held post-doctoral positions in DuPont Inc. in Delaware, US and the Medical Research Council in Cambridge, UK under the Nobel laureate Professor Sydney Brenner.


Dr. Stephen BETZ, Crinetics Pharmaceutical Inc, USA

Novel Orally Active Somotostatin Analogs

Stephen F. Betz, Ph.D., is a co-founder and the Vice President, Biology of Crinetics Pharmaceuticals. Previously, from June 2003 to May 2009, he was Director of Endocrinology and Metabolism at Neurocrine Biosciences, Inc., where he worked on the discovery and development of nonpeptide modulators of endocrine targets, including GnRH receptor antagonists, leading to the clinical development of elagolix. Prior to Neurocrine, from 2001 to 2003, he led laboratory efforts at GeneFormatics, Inc., and from 1996 to 2000, he worked in pharmaceutical discovery at Abbott Laboratories, including structure-guided drug design, assay development, and compound screening in the Research Nuclear Magnetic Resonance Group focusing on anti-infective and oncology targets. From 1993 to 1996, he worked at the Dupont Merck Pharmaceutical Company focusing on protein engineering and de novo protein design. He holds a B.S. in chemistry from the University of Delaware and a Ph.D. in chemistry from the University of North Carolina at Chapel Hill.

Follow ICN 2018:

Facebook" target="_blank">Twitter YouTube


Switch to desktop version

Conference Newsletter


Subscribe to the Newsletter to receive important information about the upcoming Conference.